One highly-touted piece of the Indianapolis-based Eli Lilly and Co. (NYSE: LLY) pipeline has returned positive results from a late-stage study. Cyramza, in combination with another drug, met its primary endpoint by showing an improvement in the progression-free survival rate among cancer patients receiving the treatment.
The Phase 3 RANGE study involved patients in various stages of urothelial carcinoma. Lilly says bladder cancer accounts for the majority of all urothelial carcinoma.
Lilly Oncology Senior Vice President of Global Development and Medical Affairs Levi Garraway says "people with advanced urothelial cancer – an aggressive disease – who have progressed on prior therapy need more treatment options that can help to control their disease. Until now, no Phase 3 study has demonstrated superior PFS over chemotherapy in this setting. These results are encouraging and we look forward to seeing the overall survival results when they are mature. Lilly would like to thank the patients, investigators and clinical trial sites that are participating in this study."
In order for the treatment to be submitted for global regulatory approvals, Lilly anticipates it must produce overall survival rate results, which aren’t expected until mid-2018.
You can connect to more about the results by clicking here.